BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead candidates with demonstrated broad-spectrum in vitro and in vivo efficacy against ...
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...
Pneumonia is swelling (inflammation) of the tissue in one or both lungs. According to the NHS, it's usually caused by a ...
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback